Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges

References

• EU Guideline on Similar Biological Medicinal Products (CHMP/437/04) (http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf)
   Google Scholar
• EU Guideline on similar biological medicinal products containing monoclonal antibodies – nonclinical and clinical issues (EMA/CHMP/BMWP/403543/2010) (http://www.ema.europa.eu/docs/en_GB /document_library/Scientific_guideline/2012/06/WC500128686.pdf)
   Google Scholar
• Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf)
   Google Scholar
• Bui LA, Hurst S, Finch GL, Ingram B, Jacobs IA, Kirchhoff CF, Ng CK, Ryan AM. Key considerations in the preclinical development of biosimilars. Drug Discovery Today 2015; 20(1): 3-15; PMID:25912284; http://dx.doi.org/10.1016/j.drudis.2015.03.011
   PubMed Web of Science ®Google Scholar
• http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/06/WC500144941.pdf
   Google Scholar
• EU Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: nonclinical and clinical issues (EMEA/CHMP/BMWP/42832/2005 Rev1). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf
   Google Scholar
• Martin PL, Bugelski PJ. Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets. British Journal of Pharmacology 2012 Jun;166 (3):806-22; PMID:22168335; http://dx.doi.org/10.1111/j.1476-5381.2011.01812.x
   PubMed Web of Science ®Google Scholar
• Bugelski PJ, Martin PL. Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets. British Journal of Pharmacology 2012 Jun;166 (3):823-46; PMID:22168282; http://dx.doi.org/10.1111/j.1476-5381.2011.01811.x
   PubMed Web of Science ®Google Scholar
• van Meer PJ, Kooijman M, van der Laan JW, Moors EH, Schellekens H. The value of non-human primates in the development of monoclonal antibodies. Nature Biotechnology 2013 Oct;31 (10):882-3; PMID:24104750; http://dx.doi.org/10.1038/nbt.2709
   PubMed Web of Science ®Google Scholar
• Bussiere JL. Species selection considerations for preclinical toxicology studies for biotherapeutics. Expert Opinion in Drug Metabolism and Toxicology 2008; 4(7):871-7; PMID:18624676; http://dx.doi.org/10.1517/17425255.4.7.871
   PubMed Web of Science ®Google Scholar
• Chapman K, Pullen N, Graham M, Ragan I. Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nature Reviews Drug Discovery 2007; 6: 120-126; PMID:17268483; http://dx.doi.org/10.1038/nrd2242
   PubMed Web of Science ®Google Scholar
• Chapman K, Andrews L, Bajramovic JJ, Baldrick P, Black LE, Bowman CJ, Buckley LA, Coney LA, Couch J, Dempster M, et al. The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in the use of non-human primates. Regulatory Toxicology and Pharmacology 2012; 62 (2): 347-54; PMID:22100994; http://dx.doi.org/10.1016/j.yrtph.2011.10.016
   PubMed Web of Science ®Google Scholar
• Chapman K, Pullen N, Coney L, Dempster M, Andrews L, Bajramovic J, Baldrick P, Buckley L, Jacobs A, Hale G, et al. Preclinical development of monoclonal antibodies. Considerations for the use of non-human primates. mAbs 2009; 1:5, 505-516; PMID:20065651; http://dx.doi.org/10.4161/mabs.1.5.9676
   PubMed Web of Science ®Google Scholar
• ICH S6 (R1). Preclinical safety evaluation of biotechnology-derived pharmaceuticals. In: International Conference on Harmonisation (ICH). Topic S6 (R1). June 2011.
   Google Scholar
• Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf)
   Google Scholar
• Krishnan A, Mody R, Malhotra, H. Global regulatory landscape of biosimilars: emerging and established market perspectives. Biosimilars 2015; 5: 19-32; http://dx.doi.org/10.2147/BS.S44052
   Google Scholar
• van Aerts LAGJM, Smet K, Reichmann G, van der Laan JW, Schneider CK. Biosimilars entering the clinic without animal studies: A paradigm shift in the European Union. mAbs 2014; 6:5, 1155-1162; PMID:25517301; http://dx.doi.org/10.4161/mabs.29848
   PubMed Web of Science ®Google Scholar
• Van Meer PJK, Ebbers HC, Kooijman M, Gispen-de Wied CC, Silva-Lima B, Moors EHM, Schellekens H. Contribution of animal studies to evaluate the similarity of biosimilars to reference products. Drug Discovery Today 2014; 120(4): 483-490; PMID:25463036; http://dx.doi.org/10.1016/j.drudis
   Google Scholar
• European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) EMA/CHMP/589317/2013. European Public Assessment Report Remsima International non-proprietary name: Infliximab
   Google Scholar
• Heim HK. Geneva, April 27 (2015): Session 3: Review of the current WHO SBPs Guidelines: Regulatory perspectives, Federal Institute for Drugs and Medical Devices (BfArM)
   Google Scholar
• Leach MW. Regulatory forum opinion piece: differences between protein-based biologic products (biotherapeutics) and chemical entities (small molecules) of relevance to the toxicologic pathologist. Toxicological Pathology 2013; 41(1):128-36; PMID:22744226; http://dx.doi.org/10.1177/0192623312451371
   PubMed Web of Science ®Google Scholar
• Schiestl M, Stangler T, Torella C, Čepeljnik T, Toll H, Grau R. Acceptable Changes in Quality Attributes of Glycosylated Biopharmaceuticals. Nature Biotechnology 2011; 29: 310-312; PMID:21478841; http://dx.doi.org/10.1038/nbt.1839
   PubMed Web of Science ®Google Scholar
• Abdiche YN, Yeung YA, Chaparro-Riggers J, Barman I, Strop P, Chin SM, Pham A, Bolton G, McDonough D, Lindquist K, et al. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. mAbs 2015; 7(2):331-43; PMID:25658443; http://dx.doi.org/10.1080/19420862.2015.1008353
   PubMed Web of Science ®Google Scholar
• Kliwinski C, Cooper PR, Perkinson R, Mabus JR, Tam SH, Wilkinson TM, Giles-Komar J, Scallon B, Powers GD, Hornby PJ. Contribution of FcRn binding to intestinal uptake of IgG in suckling rat pups and human FcRn-transgenic mice. Am J Physiol Gastrointest Liver Physiol 2013; 304(3):262-70; PMID:23220220; http://dx.doi.org/10.1152/ajpgi.00340.2012
   PubMed Web of Science ®Google Scholar
• Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001; 13(12):1551-9; PMID:11717196; http://dx.doi.org/10.1093/intimm/13.12.1551
   PubMed Web of Science ®Google Scholar
• Andersen JT, Daba MB, Berntzen G, Michaelsen TE, Sandlie I. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J Biol Chem. 2010; 12; 285(7):4826-36; PMID:20018855; http://dx.doi.org/10.1074/jbc.M109.081828
   PubMed Web of Science ®Google Scholar
• Ryan AM, Sokolowski SA, Ng C-K, Shirai N, Collinge M, Shen AC, Arrington J, Radi Z, Cummings TR, Ploch SA, et al. Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera®). Toxicological Pathology 2014; 42:1069-1081; PMID:24604381; http://dx.doi.org/10.1177/0192623313520351
   PubMed Web of Science ®Google Scholar
• Hurst S, Ryan AM, Ng C-K, McNally JM, Lorello LG, Finch GL, Leach MW, Ploch SA, Fohey JA, Smolarek TA. Comparative nonclinical assessments of the proposed biosimilar PF05280014 and trastuzumab (Herceptin®). BioDrugs 2014; 28:451-459; PMID:25001079; http://dx.doi.org/10.1007/s40259-014-0103-4
   PubMed Web of Science ®Google Scholar
• Derzi M, Ripp SL, Ng C-K, Shoieb AM, Finch GL, Lorello L, Leach MW. Comparative nonclinical assessments of the potential biosimilar PF-06410293 and adalimumab. SOT Annual Meeting, Phoenix, Arizona, March 24–27 2014
   Google Scholar
• Johnson TR, Derzi M, Bolt M, Ng C-K, Kirchhoff CF, Lorello L, McNally J, Leach MW, Smolarek TA. Comparative Nonclinical Assessments of Marketed Infliximab Presentations (Remicade®) and the Potential Biosimilar PF06438179. 14th Annual American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference, San Diego, California, May 19–21. 2014
   Google Scholar
• Ripp SL, Bolt M, Derzi M, Finch G, Hurst S, Johnson TR, Leach MW, Smolarek TA. A fit-for-purpose approach to nonclinical assessments for adalimumab and infliximab biosimilar development. 19th North American Regional ISSX Meeting and 29th JSSX Annual Meeting, San Francisco, California, October 19–23 2014.
   Google Scholar
• Peraza M, Shiue M, Phenix S, Rule K, Finch G, Thibault S, Leach MW. Comparative nonclinical assessment of the potential biosimilar PF-06439535 and bevacizumab. In: 2015 Annual Meeting Abstract Supplement, Society of Toxicology, 2015, Abstract no. 603.
   Google Scholar